Background Routine vaccination of elderly people against pneumococcal diseases is
recommended in many countries. National guidelines differ, recommending either the 23 …

Two pneumococcal vaccines currently exist and have been recommended for the prevention
of pneumococcal infection in adults 65 years of age and older: the 23-valent polysaccharide …

Background The serotype-specific effectiveness of 23-valent pneumococcal polysaccharide
vaccine (PPV23) against pneumococcal pneumonia has not been established in people …

Introduction: Routine pneumococcal vaccination for adults aged≥ 60 or≥ 65 years and
those with underlying at-risk and high-risk conditions is recommended in many countries …

Background Pneumococcal community-acquired pneumonia (pCAP) is the most frequent
form of pneumonia. The elderly and adults with underlying diseases are at an increased risk …

A 23-valent polysaccharide pneumococcal vaccine (PPV) has been available in the UK for
more than 20 years and is currently recommended for use in high-risk groups (HRG) of 2+ …

Background. The benefits of using the 23-valent pneumococcal polysaccharide vaccine
(PPV23) are controversial. This study assessed clinical effectiveness of PPV23 in preventing …

Background Data on the efficacy of the 23-valent pneumococcal polysaccharide vaccine
(PPV-23) in preventing adult community-acquired pneumonia (CAP) among the target …

Vaccination is the only public-health measure likely to reduce the burden of pneumococcal
diseases. In 2010, a group of European experts reviewed evidence on the burden of …

In 2003 the existing 23-valent pneumococcal vaccine (PPV23) programme for high risk
groups was extended to include all≥ 65 year olds in England and Wales, starting with≥ 80 …